Business Context and Reporting Period
This Form 8-K is a current report filed by AgeX Therapeutics, Inc. (trading symbol: AGE on NYSE American) on December 14, 2022. The filing discloses a new borrowing event and the issuance of unregistered equity securities. Note: The request metadata references "Serina Therapeutics, Inc.," but the filing text explicitly identifies the registrant as AgeX Therapeutics, Inc.
Key Financial Metrics and Obligations
- New Borrowing: AgeX borrowed an additional $1,000,000 under a Secured Convertible Promissory Note with Juvenescence Limited.
- Total Drawn: The cumulative amount borrowed under the line of credit is now $12,660,000.
- Remaining Capacity: $500,000 remains available for future draws, subject to lender discretion.
- Repayment Date: The outstanding principal balance is due on February 14, 2024.
- Cost of Capital: In lieu of accrued interest, the company pays an Origination Fee of 4% on each draw and an additional 4% on the total drawn amount after the 12-month draw period.
- Equity Issuance: Warrants to purchase 847,457 shares of common stock were issued at an exercise price of $0.59 per share.
Material Changes Versus Prior Period
The filing does not provide comparative financial statements (revenue, profit, or cash flow) for the period. The material change reported is the increase in debt obligations and the dilution potential from the issuance of new warrants associated with the December 14, 2022 loan draw.
Guidance, Risks, and Contingencies
- Forward-Looking Statements: The company includes standard disclaimers that actual results may differ materially from anticipated results due to various risk factors.
- Events of Default: The Secured Note contains extensive default provisions, including failure to pay principal or fees, breach of covenants, cross-defaults on other indebtedness exceeding $100,000, insolvency, bankruptcy proceedings, and material asset dispositions exceeding $250,000.
- Acceleration: Upon an Event of Default, the outstanding principal and other amounts may become immediately due and payable.
- Security: The note is secured by a Security Agreement; loss or impairment of collateral constitutes a default.
Investor Verification Checklist
- Verify the total outstanding debt balance of $12,660,000 and the remaining $500,000 credit line availability.
- Confirm the calculation of the 8% total Origination Fee (4% per draw + 4% post-draw period) and its impact on total repayment obligations.
- Review the terms of the warrants issued (847,457 shares at $0.59) to assess potential dilution.
- Monitor the company's liquidity to ensure compliance with the February 14, 2024 repayment deadline.
- Check for any other indebtedness exceeding $100,000 that could trigger a cross-default under the Secured Note.